REFERENCES
1. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, et al. Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the Japanese Breast Cancer Society. Breast Cancer 2010;17:118-24.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
4. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118:5463-72.
5. Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer 2014;17:376-85.
6. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34.
8. Lips EH, Laddach N, Savola SP, Vollebergh MA, Oonk AM, et al. Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness. Breast Cancer Res 2011;13:R107.
9. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-9.
10. Lips EH, Michaut M, Hoogstraat M, Mulder L, Besselink NJ, et al. Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Res 2015;17:134.
11. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov 2014;4:232-45.
12. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, et al. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol 2015;144:713-21.
13. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, et al. The clinical value of TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res 2006;12:1157-67.
14. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IR, et al. TP53 mutation status and gene expression profiles are powerful powerful prognositic markers of breast cancer. Breast Cancer Res 2007;9:R30.
15. Ooe A, Kato K, Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 2007;101:305-15.
